The messenger industry is presently experiencing remarkable growth, fueled by the successful deployment of mRNA-based immunizations against COVID-19. Studies suggest a evolving landscape, with ongoing funding into therapeutic applications outside infectious diseases, including areas such as oncology, rare diseases, and protein replacement therapy.